Compare ANPA & AARD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | ANPA | AARD |
|---|---|---|
| Founded | 2016 | 2017 |
| Country | Hong Kong | United States |
| Employees | 32 | 40 |
| Industry | | Biotechnology: Pharmaceutical Preparations |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 103.7M | 85.7M |
| IPO Year | N/A | N/A |
| Metric | ANPA | AARD |
|---|---|---|
| Price | $4.60 | $3.93 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 9 |
| Target Price | N/A | ★ $15.29 |
| AVG Volume (30 Days) | 5.4K | ★ 127.2K |
| Earning Date | 02-06-2026 | 05-14-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $2.80 | $3.35 |
| 52 Week High | $180.64 | $17.94 |
| Indicator | ANPA | AARD |
|---|---|---|
| Relative Strength Index (RSI) | 28.49 | 44.36 |
| Support Level | N/A | $3.38 |
| Resistance Level | $6.46 | $4.39 |
| Average True Range (ATR) | 0.50 | 0.29 |
| MACD | -0.06 | 0.06 |
| Stochastic Oscillator | 4.02 | 72.22 |
Rich Sparkle Holdings Ltd is a holding company conducting its operations as a professional specialist in the provision of financial printing services such as printing, typesetting and translation, advisory services including Environmental, Social and Governance (ESG) and internal control reporting services and other services including standalone annual general meeting and extraordinary general meeting supporting service and other standalone services, through its sole operating subsidiary in Hong Kong. Its segments include Financial printing services such as printing, typesetting and translation, Advisory services including Environmental, Social and Governance Report and Other services.
Aardvark Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing novel, small-molecule therapeutics to activate innate homeostatic pathways for the treatment of metabolic diseases. It is focused on on developing selective compounds, targeting Bitter Taste Receptors (TAS2Rs) for hunger-associated conditions. Its product candidate, ARD-101, is an oral gut-restricted small-molecule agonist of certain TAS2Rs expressed in the gut lumen for which have initiated a Phase 3 clinical trial for hyperphagia associated with PWS.